CN100536850C - 包含星孢素的组合 - Google Patents

包含星孢素的组合 Download PDF

Info

Publication number
CN100536850C
CN100536850C CNB2004800227221A CN200480022722A CN100536850C CN 100536850 C CN100536850 C CN 100536850C CN B2004800227221 A CNB2004800227221 A CN B2004800227221A CN 200480022722 A CN200480022722 A CN 200480022722A CN 100536850 C CN100536850 C CN 100536850C
Authority
CN
China
Prior art keywords
typically
phenyl
methyl
alkyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004800227221A
Other languages
English (en)
Chinese (zh)
Other versions
CN1832747A (zh
Inventor
P·W·阿塔贾
K·N·巴拉
P·S·科恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1832747A publication Critical patent/CN1832747A/zh
Application granted granted Critical
Publication of CN100536850C publication Critical patent/CN100536850C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB2004800227221A 2003-08-08 2004-08-06 包含星孢素的组合 Expired - Fee Related CN100536850C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49382803P 2003-08-08 2003-08-08
US60/493,828 2003-08-08

Publications (2)

Publication Number Publication Date
CN1832747A CN1832747A (zh) 2006-09-13
CN100536850C true CN100536850C (zh) 2009-09-09

Family

ID=34135288

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800227221A Expired - Fee Related CN100536850C (zh) 2003-08-08 2004-08-06 包含星孢素的组合

Country Status (9)

Country Link
US (1) US20070191338A1 (enExample)
EP (2) EP1653973A1 (enExample)
JP (1) JP2007501774A (enExample)
CN (1) CN100536850C (enExample)
AU (1) AU2004262927B2 (enExample)
BR (1) BRPI0413439A (enExample)
CA (1) CA2533861A1 (enExample)
MX (1) MXPA06001524A (enExample)
WO (1) WO2005014004A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2518318A1 (en) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0419159D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
EP1824831A2 (en) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CN101263121A (zh) 2005-07-14 2008-09-10 塔克达圣地亚哥公司 组蛋白脱乙酰基酶抑制剂
JP2009504608A (ja) * 2005-08-09 2009-02-05 ヨハネス・グーテンベルク−ウニヴェルジテート・マインツ 薬剤耐性肺癌のタンパク質キナーゼ阻害剤への感作
WO2007030455A2 (en) * 2005-09-07 2007-03-15 Novartis Ag Mutations and polymorphisms of hdac10
GB0522932D0 (en) * 2005-11-10 2005-12-21 Univ Southampton PKC412 in treatment of atypical chronic myeloid leukemia
GB0612542D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Combinations comprising staurosporines
EP2260020B1 (en) 2008-03-26 2014-07-23 Novartis AG Hydroxamate-based inhibitors of deacetylases b
US20110053925A1 (en) * 2009-08-28 2011-03-03 Novartis Ag Hydroxamate-Based Inhibitors of Deacetylases
CN102101866A (zh) * 2010-11-04 2011-06-22 中国海洋大学 十字孢碱卤代衍生物及其制备方法和应用
DK2872631T3 (en) 2012-07-13 2017-06-12 Turun Yliopisto COMBINATION THERAPY

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0919244A2 (de) * 1997-10-10 1999-06-02 Forschungszentrum Borstel Zentrum für Medizin und Biowissenschaften Kombinationspräparate für die Therapie von Tumoren

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62220196A (ja) 1986-03-20 1987-09-28 Kyowa Hakko Kogyo Co Ltd 新規物質ｕｃｎ―０１
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
CZ280738B6 (cs) 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
GB8803048D0 (en) 1988-02-10 1988-03-09 Hoffmann La Roche Substituted pyrroles
MC2096A1 (fr) 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
CA2046801C (en) 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
AU2866992A (en) 1991-10-10 1993-05-03 Schering Corporation 4'-(n-substituted-n-oxide)staurosporine derivatives
US5344926A (en) 1992-06-22 1994-09-06 Kyowa Hakko Kogyo Co., Ltd. Process for producing staurosporine derivatives
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
PH30300A (en) 1993-05-07 1997-01-20 Ciba Geigy Ag Polycyclic compounds and processes for the preparation thereof
AU678435B2 (en) 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
NO308798B1 (no) 1993-12-07 2000-10-30 Lilly Co Eli Proteinkinase-C-hemmere, anvendelse av samme for fremstilling av farmasøytika samt farmasøytisk formulering omfattende samme
GB9325395D0 (en) 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
EP0763040A1 (en) 1994-06-01 1997-03-19 Novartis AG Carbazole derivatives as agents against multi-drug resistance
WO1995032976A1 (en) 1994-06-01 1995-12-07 Ciba-Geigy Ag Polycyclic lactam derivatives for sensitizing multidrug-resistant cells to antitumour agents
EP0711557A1 (de) 1994-11-09 1996-05-15 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage
EP0733372A3 (de) 1995-03-21 1998-05-20 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage für Nanosuspensionen
NL1003692C2 (nl) 1996-07-26 1998-01-28 Stork Protecon Langen Bv Inrichting voor het afscheiden van vleesmassa van van vleesresten voorziene botten.
CO4940430A1 (es) 1997-07-07 2000-07-24 Novartis Ag Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AR035885A1 (es) * 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
EP1441737B1 (en) * 2001-10-30 2006-08-09 Novartis AG Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
PT1611088E (pt) * 2003-04-07 2009-09-24 Pharmacyclics Inc Hidroxamatos como agentes terapêuticos
CN1791396A (zh) * 2003-05-21 2006-06-21 诺瓦提斯公司 组蛋白脱乙酰基酶抑制剂与化疗剂的组合

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0919244A2 (de) * 1997-10-10 1999-06-02 Forschungszentrum Borstel Zentrum für Medizin und Biowissenschaften Kombinationspräparate für die Therapie von Tumoren

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Superior Activity of the Combination of Histone DeacetylaseInhibitor LAQ824 and the FLT-3 Kinase Inhibitor PKC412against Human Acute Myelogenous Leukemia Cells withMutant FLT-3. Purva Bali,et al.Clinical Cancer Research,Vol.10 No.15. 2004 *

Also Published As

Publication number Publication date
CN1832747A (zh) 2006-09-13
EP2305265A1 (en) 2011-04-06
JP2007501774A (ja) 2007-02-01
EP1653973A1 (en) 2006-05-10
CA2533861A1 (en) 2005-02-17
BRPI0413439A (pt) 2006-10-17
AU2004262927A1 (en) 2005-02-17
WO2005014004A1 (en) 2005-02-17
AU2004262927B2 (en) 2008-05-22
MXPA06001524A (es) 2006-05-15
US20070191338A1 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
CA2462657C (en) Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
CN100536850C (zh) 包含星孢素的组合
CA2527703C (en) New use of staurosporine derivatives
US20060229290A1 (en) Staurosporine derivatives for hypereosinophilic syndrome
CA2629478C (en) Staurosporine derivatives for use in alveolar rhabdomyosarcoma
AU2008202050A1 (en) Combinations comprising staurosporines
WO2006021456A1 (en) Combination comprising a staurosporine and a cyp3a4 inhibitor
AU2005313556B2 (en) Use of staurosporine derivatives for the treatment of multiple Myeloma
WO2008043811A1 (en) Staurosporine derivatives and radiation
HK1095519B (en) The use of staurosporine derivatives for the manufacture of a medicament
HK1068262B (en) Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
AU2008201869A1 (en) Staurosporine derivatives for hypereosinophilic syndrome

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090909

Termination date: 20130806